RXRX
$3.42
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...
Recent News
Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the show, talked the big game, didn’t deliver.” Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that uses […]
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion Pharmaceuticals (RXRX) reached $3.44 at the closing of the latest trading day, reflecting a -1.99% change compared to its last close.
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately
If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common yardsticks. The stock recently closed at US$3.51, with returns of a 3.3% decline over 7 days, an 11.8% decline over 30 days, a 16.4% decline year to date, and a 42.7% decline over the past year, plus a 54.2% decline over three years. Recent coverage of Recursion has focused on its profile as a...
How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors
In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and full-year 2025 net loss widened to US$644.76 million. Management also highlighted what it called an inflection point for its AI-native drug discovery platform, citing the first AI-enabled clinical proof of concept in familial adenomatous polyposis and progress across five clinical programs,...
A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results
Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its AI driven drug discovery platform. See our latest analysis for Recursion Pharmaceuticals. The latest earnings and capital raising plans come after a weak run for the stock, with a 30 day share price return of an 11.81% decline and a 1 year total shareholder return of a 42.74% decline from a...